Abstract
Background. The prognostic and predictive value of magnetic resonance (MR) investigations in clinical oncology may be improved by implementing strategies for discriminating between viable and necrotic tissue in tumors. The purpose of this preclinical study was to investigate whether the extent of necrosis in tumors can be assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and/or T2-weighted MR imaging. Material and methods. Three amelanotic human melanoma xenograft lines differing substantially in tumor necrotic fraction, necrotic pattern, extracellular volume fraction, and blood perfusion were used as experimental models of human cancer. MRI was performed at 1.5 T and a spatial resolution of 0.23 × 0.47 × 2.0 mm3. Gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA) was used as contrast agent. Plots of Gd-DTPA concentration versus time were generated for each voxel, and three parameters were calculated for each curve: the extracellular volume fraction (νe), the final slope (a), and the Gd-DTPA concentration at one minute after the contrast administration (C1min). Parametric images of νe, a, C1min, and the signal intensity in T2-weighted images (SIT2W) were compared with the histology of the imaged tissue. Results. The νe, a, and C1min frequency distributions were significantly different for necrotic and viable tissue in all three tumor lines. By using adequate values of νe, a, and C1min to discriminate between necrotic and viable tissue, significant correlations were found between the fraction of necrotic tissue assessed by MRI and the fraction of necrotic tissue assessed by image analysis of histological preparations. On the other hand, the SIT2W frequency distributions did not differ significantly between necrotic and viable tissue in two of the three tumor lines. Conclusion. Necrotic regions in tumor tissue can be identified in parametric images derived from DCE-MRI series, whereas T2-weighted images are unsuitable for detection of tumor necrosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
